# TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)

> **NCT00328523** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 1496 (actual)

## Conditions studied

- Hypercholesterolaemia
- Hyperlipidaemia

## Interventions

- **DRUG:** MK-0653, ezetimibe
- **DRUG:** Duration of Treatment: 3 months

## Key facts

- **NCT ID:** NCT00328523
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 1496 (ACTUAL)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00328523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00328523, "TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00328523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*